Filing Flows › Sutro Biopharma (STRO) › Q1 2025
Sutro Biopharma (STRO) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Sutro Biopharma (STRO) reported revenue of $17.4M for the first quarter 2025 (Q1 2025), +34% from a year earlier and +17% from the quarter before. Operating margin was -393.8%, net loss $76.0M (436.6% of revenue).
Sutro Biopharma, Q1 2025: revenue $17.4M (+34% year over year), operating margin -393.8%, net loss $76.0M, operating cash flow −$67.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17.4M | +17% | +34% |
| Operating profit | −$68.5M | — | — |
| Net earnings | −$76.0M | — | — |
| Operating cash flow | −$67.9M | — | — |
What changed
Revenue was $17.4M in Q1 2025, up 34% year over year and up 17% from the previous quarter.
Operating costs exceeded revenue by $68.5M, an operating margin of -393.8%. Total costs grew 23% against revenue growth of 34%. The quarter ended with a net loss of $76.0M, wider than the previous quarter's $72.4M loss.
Operating cash flow was −$67.9M. Non-cash charges added back $1.9M of depreciation and amortization and $5.5M of share-based compensation.
Questions
What was Sutro Biopharma's revenue in the first quarter 2025?
Sutro Biopharma (STRO) reported revenue of $17.4M for the first quarter 2025 (Q1 2025), +34% from a year earlier and +17% from the quarter before.
Was Sutro Biopharma profitable in the first quarter 2025?
Operating loss was $68.5M (-393.8% of revenue) and net loss $76.0M.
Source: Sutro Biopharma 10-Q on SEC EDGAR.